Nkarta, Inc. (NKTX) stock
NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.25+0.04 (+3.31%)
Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%
Nkarta ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Nkarta's ebitda for the twelve months ending Jun 30, 2026 was -$122.65M. For fiscal 2025 it was -$112.80M. The highest annual figure on record is -$21.95M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$112.80M | – |
| FY2024 | Dec 31, 2024 | -$118.99M | – |
| FY2023 | Dec 31, 2023 | -$125.75M | – |
| FY2022 | Dec 31, 2022 | -$116.36M | – |
| FY2021 | Dec 31, 2021 | -$84.63M | – |
| FY2020 | Dec 31, 2020 | -$50.71M | – |
| FY2019 | Dec 31, 2019 | -$21.95M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$40.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$28.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.89M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$36.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.70M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.55M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.55M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.81M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.57M | – |
See a number that looks wrong?